Suspension of trading

NeuBase Therapeutics, Inc. Stock

O7P

US64132K2015

Biotechnology & Medical Research

Delayed Deutsche Boerse AG 02:03:16 2024-05-13 EDT			5-day change	1st Jan Change
0.3406 ^EUR	-0.58%		-.--%	-

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.14M 1.06M 957K 1.79M 122M 1.82M 12.72M 5.03M 63.59M 4.8M 4.69M 201M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.14M 1.06M 957K 1.79M 122M 1.82M 12.72M 5.03M 63.59M 4.8M 4.69M 201M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news: NeuBase Therapeutics, Inc.

25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
25-01-07	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
24-06-27	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
24-05-28	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	2021-10-31

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	2025-01-03

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-0.58%	-.--%	-.--%	-45.50%	1.39M
WUXI APPTEC CO., LTD.	-3.10%	-3.43%	+36.29%	+67.69%	65.28B
ARGENX SE	+0.10%	0.00%	+9.79%	+77.48%	54.57B
LONZA GROUP AG	-0.05%	+1.38%	+9.51%	+101.40%	53.59B
IQVIA HOLDINGS INC.	+0.58%	+2.47%	+26.23%	+52.53%	45.03B
BEONE MEDICINES AG	-2.32%	-5.54%	+15.14%	+113.08%	42.17B
REVOLUTION MEDICINES, INC.	+0.77%	-5.04%	+221.85%	+902.90%	39.42B
CELLTRION, INC.	-0.74%	-4.84%	+14.53%	+44.45%	32.71B
WUXI BIOLOGICS (CAYMAN) INC.	-2.70%	-7.34%	+23.17%	+0.36%	24.01B
GENMAB A/S	+1.21%	+15.33%	+60.48%	+49.53%	26.5B
Average	-0.68%	+1.36%	+41.70%	+136.39%	38.33B
Weighted average by Cap.	-0.78%	+1.72%	+43.34%	+155.45%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company